<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02299999</url>
  </required_header>
  <id_info>
    <org_study_id>UC-0105/1304</org_study_id>
    <secondary_id>2013-001652-36</secondary_id>
    <nct_id>NCT02299999</nct_id>
  </id_info>
  <brief_title>SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer</brief_title>
  <acronym>SAFIR02_Breast</acronym>
  <official_title>PERSONALIZED MEDICINE GROUP / UCBG UC-0105/1304: SAFIR02_Breast - Evaluation of the Efficacy of High Throughput Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UNICANCER</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fondation ARC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>UNICANCER</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Open label multicentric phase II randomized trial, using high throughput genome analysis as a&#xD;
      therapeutic decision tool, which aims at comparing a targeted treatment administered&#xD;
      according to the identified molecular anomalies of the tumor with maintenance chemotherapy&#xD;
      (targeted substudy 1) as well as immunotherapy with maintenance chemotherapy in patients&#xD;
      without actionable genomic alterations or non eligible to substudy 1 (immune substudy 2).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Screening phase:&#xD;
&#xD;
      New frozen biopsy or an archived frozen sample or ctDNA sample will be sent to the genomic&#xD;
      platforms for DNA extraction and genomic analysis (DNA microarrays and Next generation&#xD;
      sequencing).&#xD;
&#xD;
      Patients can be considered as pre-eligible for the targeted substudy 1 randomisation phase&#xD;
      when both following mandatory conditions have been met: stable or responding disease has been&#xD;
      observed (investigator judgment) after 6 to 8 cycles of chemotherapy (or at least after 4&#xD;
      cycles of chemotherapy if stopped for toxicity) and targetable alteration has been identified&#xD;
      by the Molecular Tumor Board (MTB).&#xD;
&#xD;
      If not eligible for the substudy 1 randomisation phase, patients can be considered as&#xD;
      pre-eligible for the immune substudy 2 randomization phase when both following mandatory&#xD;
      conditions are met: stable or responding disease (investigator judgment) is observed after 6&#xD;
      to 8 cycles of chemotherapy (or at least after 4 cycles if treatment was stopped due to&#xD;
      toxicity) AND not eligible to randomization in the substudy 1 (because patient had no&#xD;
      targetable alteration identified by the Molecular Tumor Board, or failed to have a genomic&#xD;
      profile for the tumor [low tumor cells percentage, technical issue during genomic analysis,&#xD;
      etc.], or a non inclusion criteria that precluded entry into the substudy 1)&#xD;
&#xD;
      Randomization phase:&#xD;
&#xD;
      The mandatory post-chemotherapy wash-out period, of 28 days for 21 or 28 day-cycle&#xD;
      chemotherapies or of 15 days for weekly (except monoclonal antibodies) or daily&#xD;
      chemotherapies,will provide time to achieve all the required tests and examinations.&#xD;
&#xD;
      The randomization program will allocate the following treatments with a 2:1 ratio in favor of&#xD;
      Arm A of the considered substudy:&#xD;
&#xD;
      Substudy 1 : targeted therapies versus standard maintenance chemotherapy&#xD;
&#xD;
        -  Arm A1 / targeted arm: targeted maintenance from a list of 8 targeted drugs guided by&#xD;
           the genomic analysis, or&#xD;
&#xD;
        -  Arm B1 / chemotherapy arm : maintenance chemotherapy (or no antineoplastic treatment in&#xD;
           case of toxicity at the time of randomization)&#xD;
&#xD;
      Substudy 2 : immunotherapy versus standard maintenance chemotherapy&#xD;
&#xD;
        -  Arm A2 / immunotherapy maintenance arm: MEDI4736 or&#xD;
&#xD;
        -  Arm B2 / chemotherapy arm: chemotherapy continued as a maintenance chemotherapy (or no&#xD;
           antineoplastic treatment in case of toxicity)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 7, 2014</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival in the targeted drug arm compared to standard maintenance therapy arm</measure>
    <time_frame>from randomization to disease progression or death from any cause, whichever comes first, up to 16 months (estimated treatment duration average: 4 months)</time_frame>
    <description>To evaluate whether treatment with targeted agents guided by high throughput molecular analysis (CGH array, next generation sequencing) improves progression-free survival as compared to standard maintenance therapy in patients with metastatic Breast Cancer</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>progression-free survival in patients treated with anti-PDL1 antibody (MEDI4736) compared to standard maintenance therapy arm</measure>
    <time_frame>from randomization to disease progression or death from any cause, whichever comes first, up to 16 months (estimated treatment duration average: 4 months)</time_frame>
    <description>To evaluate whether treatment with MEDI4736 improves progression-free survival as compared to standard maintenance therapy in patients with metastatic Breast Cancer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival in each substudy</measure>
    <time_frame>from randomization to death (any cause), up to 16 months</time_frame>
    <description>To evaluate whether treatment with targeted agents guided by high throughput molecular analysis (CGH array, next generation sequencing) or MEDI4736 improves overall survival as compared to standard maintenance therapy in patients with metastatic Breast Cancer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall response rates and changes in tumor size in each substudy</measure>
    <time_frame>tumor response is assessed every 21 days from treatment initiation until first progression or death from any cause, whichever comes first, up to 16 months (estimated treatment duration average: 4 months)</time_frame>
    <description>tumor response is defined as a complete or partial response, upon RECIST v1.1 criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>evaluate safety, in each substudy</measure>
    <time_frame>toxicities will be assessed during the whole treatment period (4 months expected in average) followed by a 1-year post-treatment follow-up period, and reported during the visits scheduled by the study flow chart</time_frame>
    <description>Toxicities are graded according to the CTCAE V4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>efficacy (response rate, change in tumor size, progression-free survival, overall survival) and safety of each individual targeted agent (substudy 1)</measure>
    <time_frame>tumor response is assessed every 21 days from treatment initiation until first progression or death from any cause, whichever comes first, up to 16 months (estimated treatment duration average: 4 months)</time_frame>
    <description>tumor response is defined as a complete or partial response, upon RECIST v1.1 criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>correlate molecular characteristics in patients with the efficacy endpoints (response rate, progression-free and overall survival) in each substudy</measure>
    <time_frame>from randomization or treatment initiation to disease progression or death from any cause, whichever comes first, up to 16 months (estimated treatment duration average: 4 months)</time_frame>
    <description>tumor response is defined as a complete or partial response, upon RECIST v1.1 criteria</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">1460</enrollment>
  <condition>Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Substudy 1: targeted agent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm A1 / Targeted Arm : targeted maintenance from a list of 8 targeted drugs guided by the genomic analysis, AZD2014 tablet per os 50 mg bd, continuous dosing, AZD4547 tablet per os 80 mg bd, 2 weeks on/1 week off, AZD5363 capsule per os 480 mg bd, 4 days on/3 days off, AZD8931 tablet per os 40 mg bd, continuous dosing, selumetinib capsule per os 75 mg bd, continuous dosing, vandetanib tablet per os 300 mg od, continuous dosing, bicalutamide tablet per os 150 od, continuous dosing, olaparib tablet per os 300 mg bd, continuous dosing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Substudy 1: standard maintenance therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm B1/ maintenance Standard Chemotherapy Arm : such as Anthracyclines (Doxorubicin or Epirubicin or Liposomal Doxorubicine), Taxanes (Paclitaxel, Docetaxel), Cyclophosphamide, DNA Intercalators (Capecitabine, 5-FU, gemcitabine), Methotrexate, Vinca alkaloids (Vinorelbine, Vinblastine, Vincristine), Platinum based chemotherapies (Carboplatin, Cisplatin), Bevacizumab, Mitomycin C, Eribulin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Substudy 2: Immunotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm A2/ Immunotherapy arm: maintenance with MEDI4736 for patient without actionable genomic alterations or non eligible to Targeted substudy 1, MEDI4736 Intra-venous 10 mg/kg, Q2W</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Substudy 2: standard maintenance therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm B2/ maintenance Standard Chemotherapy Arm : such as Anthracyclines (Doxorubicin or Epirubicin or Liposomal Doxorubicine), Taxanes (Paclitaxel, Docetaxel), Cyclophosphamide, DNA Intercalators (Capecitabine, 5-FU, gemcitabine), Methotrexate, Vinca alkaloids (Vinorelbine, Vinblastine, Vincristine), Platinum based chemotherapies (Carboplatin, Cisplatin), Bevacizumab, Mitomycin C, Eribulin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD2014</intervention_name>
    <description>Target: m-TOR</description>
    <arm_group_label>Substudy 1: targeted agent</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD4547</intervention_name>
    <description>Target: EGFR</description>
    <arm_group_label>Substudy 1: targeted agent</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD5363</intervention_name>
    <description>Target: AKT</description>
    <arm_group_label>Substudy 1: targeted agent</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD8931</intervention_name>
    <description>Target: HER2, EGFR</description>
    <arm_group_label>Substudy 1: targeted agent</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Selumetinib</intervention_name>
    <description>Target: MEK</description>
    <arm_group_label>Substudy 1: targeted agent</arm_group_label>
    <other_name>ARRY-142866</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vandetanib</intervention_name>
    <description>Target: VEGF, EGFR</description>
    <arm_group_label>Substudy 1: targeted agent</arm_group_label>
    <other_name>CAPRELSA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bicalutamide</intervention_name>
    <description>target: Androgen receptor</description>
    <arm_group_label>Substudy 1: targeted agent</arm_group_label>
    <other_name>Casodex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olaparib</intervention_name>
    <description>Target: PARP</description>
    <arm_group_label>Substudy 1: targeted agent</arm_group_label>
    <other_name>Lynparza</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anthracyclines</intervention_name>
    <description>DNA intercalation</description>
    <arm_group_label>Substudy 1: standard maintenance therapy</arm_group_label>
    <arm_group_label>Substudy 2: standard maintenance therapy</arm_group_label>
    <other_name>Doxorubicin, Epirubicin, liposomal doxorubicin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Taxanes</intervention_name>
    <description>Target: mitotic tubulin and microtubules</description>
    <arm_group_label>Substudy 1: standard maintenance therapy</arm_group_label>
    <arm_group_label>Substudy 2: standard maintenance therapy</arm_group_label>
    <other_name>paclitaxel</other_name>
    <other_name>docetaxel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>Alkylating agents</description>
    <arm_group_label>Substudy 1: standard maintenance therapy</arm_group_label>
    <arm_group_label>Substudy 2: standard maintenance therapy</arm_group_label>
    <other_name>Novatrex</other_name>
    <other_name>Imeth</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DNA intercalators</intervention_name>
    <description>DNA intercalators</description>
    <arm_group_label>Substudy 1: standard maintenance therapy</arm_group_label>
    <arm_group_label>Substudy 2: standard maintenance therapy</arm_group_label>
    <other_name>capecitabine</other_name>
    <other_name>5-FU</other_name>
    <other_name>gemcitabine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>DNA intercalators</description>
    <arm_group_label>Substudy 1: standard maintenance therapy</arm_group_label>
    <arm_group_label>Substudy 2: standard maintenance therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vinca alkaloids</intervention_name>
    <description>Target: mitotic tubulin and microtubules</description>
    <arm_group_label>Substudy 1: standard maintenance therapy</arm_group_label>
    <arm_group_label>Substudy 2: standard maintenance therapy</arm_group_label>
    <other_name>vinorelbine</other_name>
    <other_name>vinblastine</other_name>
    <other_name>vincristine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Platinum based chemotherapies</intervention_name>
    <description>Platinum based chemotherapies</description>
    <arm_group_label>Substudy 1: standard maintenance therapy</arm_group_label>
    <arm_group_label>Substudy 2: standard maintenance therapy</arm_group_label>
    <other_name>Platinum</other_name>
    <other_name>carboplatin</other_name>
    <other_name>cisplatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Target: VEGF</description>
    <arm_group_label>Substudy 1: standard maintenance therapy</arm_group_label>
    <arm_group_label>Substudy 2: standard maintenance therapy</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mitomycin C</intervention_name>
    <description>Alkylating agents</description>
    <arm_group_label>Substudy 1: standard maintenance therapy</arm_group_label>
    <arm_group_label>Substudy 2: standard maintenance therapy</arm_group_label>
    <other_name>Ametycine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eribulin</intervention_name>
    <description>Microtubule modulator</description>
    <arm_group_label>Substudy 1: standard maintenance therapy</arm_group_label>
    <arm_group_label>Substudy 2: standard maintenance therapy</arm_group_label>
    <other_name>Halaven</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MEDI4736</intervention_name>
    <description>Target: PD-L1</description>
    <arm_group_label>Substudy 2: Immunotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Screening phase:&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Women (or men) with histologically proven breast cancer&#xD;
&#xD;
          -  Metastatic relapse or progression or stage IV at diagnosis&#xD;
&#xD;
          -  No Her2 over-expression&#xD;
&#xD;
          -  Patients with metastases that can be biopsied, except bone metastases&#xD;
&#xD;
          -  Patients who are eligible for a first or a second line of chemotherapy in metastatic&#xD;
             setting (left to the discretion of investigators), or who are currently treated with a&#xD;
             first or second line of chemotherapy with a maximum of 2 cycles at the time of biopsy.&#xD;
             Screening of patients currently treated with a second line chemotherapy should have a&#xD;
             stable disease&#xD;
&#xD;
          -  For patients with ER+ disease, relapse or progression occurred during endocrine&#xD;
             therapy, whatever the line, or less than 12 months after the end of endocrine therapy&#xD;
             in adjuvant context&#xD;
&#xD;
          -  Age ≥18 years&#xD;
&#xD;
          -  WHO Performance Status 0/1&#xD;
&#xD;
          -  Presence of measurable target lesion according to RECIST criteria v1.1&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Spinal cord compression and/or symptomatic or progressive brain metastases&#xD;
&#xD;
          -  Bone metastases when this is the only site of biopsiable disease&#xD;
&#xD;
          -  Patients with all target lesions in a previously irradiated region, except if clear&#xD;
             progression has been observed prior to study in at least one of them&#xD;
&#xD;
          -  Patient who received more than 2 lines of chemotherapy at the time of the biopsy&#xD;
&#xD;
          -  Tumor progression observed with the current line of treatment when under 2nd line&#xD;
&#xD;
          -  Patients who already had a genomic profile (both CGH and NGS analysis) in which no&#xD;
             SAFIR02 targetable alterations have been identified&#xD;
&#xD;
          -  Abnormal coagulation contraindicating biopsy&#xD;
&#xD;
          -  Inability to swallow&#xD;
&#xD;
          -  Major problem with intestinal absorption Any clinically important abnormalities in&#xD;
             rhythm, conduction or morphology of resting ECG Any factors increasing the risk of QTc&#xD;
             prolongation or arrhythmic events Experience of any of the following in the preceding&#xD;
             12 months: coronary artery bypass graft, angioplasty, vascular stent, myocardial&#xD;
             infarction, past or current uncontrolled angina pectoris, congestive heart failure&#xD;
             NYHA Grade ≥2, torsades de pointes, current uncontrolled hypertension, cardiomyopathy&#xD;
             Past medical history of interstitial lung disease, drug-induced interstitial disease,&#xD;
             radiation pneumonitis which requires steroid treatment or any evidence of clinically&#xD;
             interstitial lung disease Previous or current malignancies of other histologies within&#xD;
             the last 5 years, Evidence of severe or uncontrolled systemic disease (active bleeding&#xD;
             diatheses, or active Hepatitis B, C and HIV)&#xD;
&#xD;
          -  diagnosis of acne rosacea, severe psoriasis and severe atopic eczema&#xD;
&#xD;
          -  Prior exposure to anthracyclines or mitoxantrone with cumulative exposure in excess of&#xD;
             360 mg/m² for doxorubicin, 720 mg/m² for epirubicin, or 72 mg/m² for mitoxantrone&#xD;
&#xD;
          -  Previous treatment with the same agent or in the same class as one of those used in&#xD;
             the SAFIR02 trial (patients who received this previous targeted agent without the&#xD;
             target prescreening are eligible but may not be eligible for randomisation in substudy&#xD;
             1 if the treatment allocated by the MTB is in the same class) History of retinal&#xD;
             degenerative disease, eye injury or corneal surgery in the previous 3 months, past&#xD;
             history of central serous retinopathy or retinal vein occlusion, intraocular pressure&#xD;
             &gt;21 mmHg, or uncontrolled glaucoma.&#xD;
&#xD;
          -  History of hemorrhagic or thrombotic stroke, TIA or other CNS bleeds&#xD;
&#xD;
          -  Renal disease including glomerulonephritis, nephritic syndrome, Fanconi syndrome,&#xD;
             renal tubular acidosis&#xD;
&#xD;
          -  Patients using drugs that are known potent inhibitors or potent inducers or substrates&#xD;
             of cytochrome P450&#xD;
&#xD;
        Randomized phase:&#xD;
&#xD;
        Substudy 1:&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients who received 6 to 8 cycles of chemotherapy, or having received at least 4&#xD;
             cycles of chemotherapy definitively stopped for toxicity reasons, and who are&#xD;
             presenting a SD or PR at randomization&#xD;
&#xD;
          -  presenting at least one genomic alteration from the predefined list&#xD;
&#xD;
          -  Age ≥25 years for patients planned to receive AZD4547&#xD;
&#xD;
          -  28-day wash-out period from chemo prior to randomization and grade ≤1 residual&#xD;
             toxicities&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  More than 2 previous lines of chemotherapy for metastatic disease before randomization&#xD;
&#xD;
          -  Life expectancy &lt;3 months&#xD;
&#xD;
          -  Disease progression occuring at any time during chemotherapy and before randomization&#xD;
             or toxicity that led to the discontinuation of the last chemotherapy before 4 full&#xD;
             cycles have been delivered&#xD;
&#xD;
          -  Less than 28 days from radiotherapy, less than 2 weeks from palliative radiation&#xD;
&#xD;
          -  Patients previously treated with a targeted agent in the same class as the agent to be&#xD;
             given to the patient in substudy 1&#xD;
&#xD;
          -  Toxicities of grade ≥2 from any previous anti-cancer therapy&#xD;
&#xD;
          -  Altered haematopoietic or organ function&#xD;
&#xD;
          -  Mean resting corrected QT interval (QTc) &gt;480 msec (or QTcF &gt;450 msec) obtained from 3&#xD;
             consecutive ECGs&#xD;
&#xD;
          -  Left ventricular ejection fraction (LVEF) &lt;55% (MUGA scan or Echocardiogram)&#xD;
&#xD;
          -  Altered ophthalmic conditions confirmed by an ophthalmology specialist for patients&#xD;
             likely to be treated with AZD4547 orAZD8931 or Selumetinib&#xD;
&#xD;
          -  Patients using non-substitutable drugs, that are known to prolong QT interval or&#xD;
             induce Torsades de Pointes, when they are supposed to be treated with vandetanib,&#xD;
             AZD5363 or AZD8931&#xD;
&#xD;
        Substudy 2:&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients who received 6 to 8 cycles of chemotherapy, or having received at least 4&#xD;
             cycles of chemotherapy definitively stopped for toxicity reasons, and who are&#xD;
             presenting a SD or a RP at randomization&#xD;
&#xD;
          -  Patients not eligible to substudy 1&#xD;
&#xD;
          -  wash-out period of at least 15 days for weekly (except monoclonal antibodies) or daily&#xD;
             chemotherapies or 28 days for other chemotherapies from last chemotherapy&#xD;
             administration prior to randomization and grade ≤1 residual toxicities&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  More than 2 previous lines of chemotherapy for metastatic disease before randomization&#xD;
&#xD;
          -  Life expectancy &lt;3 months&#xD;
&#xD;
          -  Disease progression occuring at any time during chemotherapy and before randomization&#xD;
             or toxicity that led to the discontinuation of the last chemotherapy before 4 full&#xD;
             cycles have been delivered&#xD;
&#xD;
          -  Any previous treatment with a PD1 or PD-L1 inhibitor, including MEDI4736&#xD;
&#xD;
          -  Toxicities of grade ≥2 from any previous anti-cancer therapy&#xD;
&#xD;
          -  Altered haematopoietic or organ function&#xD;
&#xD;
          -  Mean resting QT interval corrected for heart rate (QTc) ≥470 ms calculated from 3&#xD;
             consecutive ECGs using Bazett's Correction&#xD;
&#xD;
          -  Current or prior use of immunosuppressive medication within 28 days before the first&#xD;
             dose of MEDI4736, with the exceptions of intranasal and inhaled corticosteroids or&#xD;
             systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of&#xD;
             prednisone, or an equivalent corticosteroid&#xD;
&#xD;
          -  Active or prior documented autoimmune disease within the past 2 years NOTE: Subjects&#xD;
             with vitiligo, Grave's disease, or psoriasis not requiring systemic treatment (within&#xD;
             the past 2 years) are not excluded&#xD;
&#xD;
          -  History of primary immunodeficiency&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fabrice ANDRE, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gustave Roussy, Villejuif</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut de Cancérologie de l'Ouest/Paul Papin</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Sainte-Catherine</name>
      <address>
        <city>Avignon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Polyclinique Bordeaux Nord Aquitaine</name>
      <address>
        <city>Bordeaux</city>
        <zip>33077</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Bergonié</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre François Baclesse</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Jean Perrin</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Georges François Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chd Vendee</name>
      <address>
        <city>La Roche-sur-Yon</city>
        <zip>85925</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Dupuytren</name>
      <address>
        <city>Limoges</city>
        <zip>87000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmettes</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Régional du Cancer Montpellier Val d'Aurelle</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Alexis Vautrin</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de l'Ouest/ René Gauducheau</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Eugène Marquis</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Saint-Cloud</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopitaux Universitaire de Strasbourg - Hopital Civil</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopitaux Du Leman</name>
      <address>
        <city>Thonon-les-Bains</city>
        <zip>74200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.unicancer.fr/</url>
    <description>Unicancer official website</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/24508104</url>
    <description>SAFIR01 study results</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>October 1, 2014</study_first_submitted>
  <study_first_submitted_qc>November 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 24, 2014</study_first_posted>
  <last_update_submitted>September 8, 2021</last_update_submitted>
  <last_update_submitted_qc>September 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Vinorelbine</mesh_term>
    <mesh_term>Vinblastine</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Vinca Alkaloids</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Durvalumab</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
    <mesh_term>Olaparib</mesh_term>
    <mesh_term>Mitomycins</mesh_term>
    <mesh_term>Mitomycin</mesh_term>
    <mesh_term>Bicalutamide</mesh_term>
    <mesh_term>Taxane</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

